AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05602363. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Study identification
- NCT ID
- NCT05602363
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 120 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 1, 2023 (Actual)
- Primary completion
- Sep 2027 (Estimated)
- Completion
- Sep 2027 (Estimated)
- Last update posted
- Dec 10, 2025
2023 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Irvine Health | Orange | California | 92868 | Recruiting |
| Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | 33140 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Northwestern Memorial Hospital | Chicago | Illinois | 60661 | Recruiting |
| American Oncology Partners | Fort Wayne | Indiana | 46804 | Recruiting |
| University of Maryland Medical Center - Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | Recruiting |
| University of Massachusetts Memorial Medical Center | Worcester | Massachusetts | 01655 | Recruiting |
| Optum Medical Care PC | Westbury | New York | 11590 | Recruiting |
| Duke University | Durham | North Carolina | 27705 | Recruiting |
| Taylor Cancer Research Center | Maumee | Ohio | 43537 | Recruiting |
| Oncology Consultants | Houston | Texas | 77030 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| The Medical College of Wisconsin | Milwaukee | Wisconsin | 53266 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05602363, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.